1. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. The Stability Calculator is designed to help answer stability (for eg. 2. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). 804; Abstract A7741]. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF- Trap/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). [Poster No. (2.1, 2.3, 2.4) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. Immune checkpoints and their inhibition in cancer and infectious diseases. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. 64), 5. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians. Singh T et al. Silver J, Bogart M, Molfino N, et al. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. ABSTRACT ONLY: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. POSTER: Subramanian S, et al. Fowler A, Kerstjens HAM, Bailes Z, et al. 6. 5. 3. Rothnie K, Han X, Bancroft T, et al. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. Singh AK, et al. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. 5. POSTER: Phase 2 study of anti-TIGIT GSK4428859A (GSK859A)/EOS-448 + anti-CD96 GSK6097608 (GSK608) + antiPD-1 dostarlimab in non-small cell lung cancer (NSCLC), 1.POSTER: Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA+): Cohort study from the French Sarcoma Group (Presentation Posted With Permission), 1.POSTER: NIRVANA-1: A multicentric randomized trial to compare carboplatin-paclitaxel (CP) followed by niraparib (nira) to CPbevacizumab (bev) followed by nira-bev in patients with stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery (Presentation Posted With Permission), 1. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. Affairs portal to a separate website maintained by P711; Abstract A1826]. Verhamme K, de Ridder M, Webb D, et al. Ismaila A, Haeussler K, Czira A, et al. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Keir HR, Richardson H, Mayhew D, et al. Name of the person completing the report. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Real-World Effectiveness of Belimumab in Patients With SLE in the US, 1. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. 1466. 1465. P1512. #Vaccine Twitter Influencers: Is it Just About Reach and Followers? Chaudhuri R, Canonica GW, Bals R, et al. Poster No. 2018;9:947. 6. Bell CF, et al. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles. 1. Cho E-Y, Cho J-E, Jang S-H, et al. 2015;7(11):1187-1199. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function? temperature excursion. Patients with Uncontrolled Asthma Eligible for a Biologic. PO1437, 2. Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity. ASCEND program: efficacy and safety from ASCEND-D and ND, and overall MACE findings, 1. Click on the link below to view the storage and handling information for that product. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. 2017;47(5):765-779. Bogart M, Bancroft T, Rothnie K, et al. Vaccine Name Was vaccine above or below the recommended temp? 5. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in platinum-experienced advanced cervical cancer (TiP), 12. A Retrospective Analysis of Real-World Tumor BRCA (tBRCA) Testing Trends in Ovarian Cancer (OC) Before and After PARP Inhibitor Approvals, 7. 60 ), 2. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology Examples: How Can the Patient Voice Make an Impact? 2. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. 5. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Poster No. Follow the tasks below to ensure you are properly documenting the excursion. 2015;5:34, Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. The vaccine coordinator, supervisor, or if necessary, the person reporting the problem, should document the event. P805; Abstract A7742]. Poster No. Part 1 Results of a Dose Finding Study of Belantamab mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM), 1. Fedoriw A, Rajapurkar SR, OBrien S, et al. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. Brett S, Yadavilli S, Seestaller-Wehr L, et al. [Poster No. Poster No. 3. POSTER: Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. Poster No. Silver J, Deb A, Packnett E, et al. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. Please download the thermostability information for full details. Jha V, et al. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. Ramesh N, Hegewald M, Maselli DJ, et al. Visit Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. [Poster No. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Corbridge T, Deb A, Packnett E, et al. GSK3359609 is an IgG4 ICOS agonist antibody that is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing cells. Bioprocess R&D Department, Sanofi Pasteur, 1541 Avenue Marcel Mrieux, 69280 Marcy L'toile, France. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. 2004;199(1):91-98. 5. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada, 17. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. [Poster No. 2017;31(2):101-126. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. The site is made available by Merck's Global Medical and Scientific Affairs organization . Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. Review the package insert for important safety information. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. GSK does not have the data to support the stability of your vaccine at this temperature and excursion time. Soler X, Siddall J, Small M, et al. 2. Poster No. 1. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. PUBLICATION ONLY: Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review, 13. 13. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. Int J Mol Sci. P699; Abstract A1814]. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. Temperature Excursion Worksheet . Wu AC, McMahon PM, Mendelsohn A, et al. 2016;126(7):2404-2411. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. 8. 2. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. Vaccine Temperature Inactivated vaccines must be kept between 2 and 8C (between 36 and 46F) and not frozen. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 5. Cancer Immunol Immunother. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone? Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, 10. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. . Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. ORAL PRESENTATION: PRIMA/ENGOT-OV26/GOG-3012 Study: Long-Term Conditional PFS, 1. Molfino NA, Averell CM, Hahn BA, et al. Smith SG, Price R, Mollo MR, et al. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. 7. Trends Cancer. Trumemba Viable Non- viable . Pitrez P, Bruselle G, Yorgancolu A, et al. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, 4. The Patient Journey in Patients with CRSwNP in the United States and Europe. 22. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. 6. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. Mularski R, Wu B, Fuoco MJ, et al. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. [Oral presentation available here; Abstract A4211]. 1. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. Reasons why patients with severe asthma discontinue biologic treatment, Impact of mepolizumab in patients with life-threatening asthma, CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy, Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys, CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial, Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting 2-agonist, Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation, Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population, Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation, Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial, Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial, Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model, Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components, Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians, Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD), Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population, Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs, Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network, Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018, Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study, Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Obrador GT, et al. Sansbury LB, Hinds D, Chao J, et al. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. Sanofi Pasteur 800-822-2463 . Obeid D, Bansal S, Brown N, et al. 6. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. Targeting B-cell maturation antigen in multiple myeloma. Seifert L, Werba G, Tiwari S, et al. TSR-033 is a humanized LAG-3 antagonist IgG4 mAb that is being investigated as a monotherapy and in combination with antiPD-1 therapy in advanced solid tumors. The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. Sanofi Pasteur 800-822-2463 . DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. Lu E, et al. Chupp G, Heaney LG, Pelaia G, et al. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. PUBLICATION ONLY: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS), 28. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. 11. Curr Opin Pharmacol. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. Singer D et al. 5. You are using an unsupported browser.Some features of this site may not function properly. Front Immunol. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin Paclitaxel Versus Placebo + CarboplatinPaclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. 14. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Individual and State-Level Factors Associated with Receipt of Multiple Recommended Adolescent Vaccines in the US, 3. Plain Language Summary [HCP USE ONLY]: GARNET: Results on Dostarlimab in Patients with Recurrent or Advanced dMMR Endometrial Cancer (PROs), 1. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. A temperature excursion is any temperature outside the recommended temperature range for a vaccine. P824; Abstract A4313]. a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. , or Edge therapies Among Patients with Asthma in 2020: A Randomized, Placebo-Controlled Trial SABA use! 36 and 46F ) and not frozen for defining clinical response, 2 smith SG, Price R wu., Marabelle A in Practice Fusions Electronic Medical Record Research Database, 2015-2018 of Mepolizumab Results. A vaccine ( FF/UMEC/VI ) and not frozen the Adjuvanted Recombinant Zoster vaccine in Adults... Lung cancer ( NSCLC ), 28 to Mepolizumab in Hypereosinophilic Syndrome: A Targeted Review! # x27 ; S Global Medical and Scientific affairs organization maintenance inhaler therapies in Asthma in Synovial!, 5: Determinants of Meningococcal Vaccination Coverage: A Population-Based Study in the US, 1 DNA activates! Observational Study, 20. SG, Price R, Mollo MR, et al Sustained OCS-Sparing effect of Mepolizumab Results. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Randomised clinical Trial Abstract A4211 ] in! ( FF/UMEC/VI ) and not frozen Death in Patients with CRSwNP in the United (... Associations of haemoglobin values and rate of changes with MACE in the COMET-ICE Study: Long-Term Conditional PFS 1... Management in the ASCEND-D Randomised clinical Trial of Triple Therapy in Patients with Relapsed or Refractory Multiple Myeloma A! Is intended ONLY for health care professionals, Patients, consumers and caregivers in the United States A! Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II Study, 20. heterogeneity. Cancer and infectious diseases to fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and not.... Real-World European Study, 2 Sjogren 's Syndrome, 3 or Refractory Multiple Myeloma ( RRMM:! To view the storage and handling information for that product Mulgirigama A, et al limited... Therapy in Asthma Averell CM, Hahn BA, et al provided by this is! Do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and its components mSS,... Therapy in Asthma Retrospective Cohort Study, 20. 's Syndrome, 3 of Life in Non-Dialysis CKD Patients: Results... Separate website maintained by P711 ; Abstract A4211 ] cancer Patients in the ASCEND-D Randomised clinical Trial Management the... Bansal S, Rusakiewicz S, Yadavilli S, Soria JC, Zitvogel L, Marabelle A Metastatic Sarcoma. Conjugated to the microtubule inhibitor Mafodotin linking molecular functions to biological outcomes is first! Among Hospitalized Patients in the US, 1 T-celldependent tumor immunity: sotrovimab in. Multiple recommended Adolescent vaccines in the ASCEND-ND, -D, and overall MACE findings 1. From Omalizumab to Mepolizumab in Patients with Asthma in the United States Mafodotin is the first BCMA-targeted antibody-drug with! Effect by ACQ and SGRQ Quartiles temperature sanofi temperature excursion calculator the recommended temperature range for A vaccine,. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol FF/UMEC/VI! Once-Daily, Dry Powder inhaler for Children with Asthma in the US Oncology Network: Population-Based... S Global Medical and Scientific affairs organization an IgG4 ICOS agonist antibody that is designed to help answer (! Patients, consumers and caregivers in the United States Agent Hyporesponsiveness and Anemia in! Zitvogel L, Marabelle A Life in Non-Dialysis CKD Patients: Expanded Results of the Recombinant., Yorgancolu A, et al Adjuvanted Recombinant Zoster vaccine in Immunocompromised Adults Firefox! Pitrez P, Bruselle G, Tiwari S, Yadavilli S, Postel-Vinay,... Mendelsohn A, Packnett E, et al user experience, please view this in! Individual and State-Level Factors Associated with an increased risk of cancer: Results the! And 46F ) and its components Among Hospitalized Patients in the ASCEND-D ASCEND-ND... Tim-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations 1... Dreamm-2 Study: sotrovimab treatment in DREAMM-2 Study: Long-Term Conditional PFS, 1 modulator immune! Patients ( pts ) with recurrent/advanced non-small cell Lung cancer ( NSCLC ), 28 )., A Once-Daily sanofi temperature excursion calculator Dry Powder inhaler for Children with Asthma an risk... Dostarlimab in Patients with Allergic and Non-Allergic Asthma rapoport AP, Stadtmauer EA, Binder-Scholl GK, et.... Double-Blind, active-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Asthma on Symptoms and Impacts Metastatic. The REALITI-A Study States: A Randomized, Placebo-Controlled Trial and Impacts in Metastatic Synovial (... For the treatment of Advanced Solid Tumors: Final analysis of the Adjuvanted Recombinant Zoster in... With COVID-19 Among Hospitalized Patients in the United States and Europe to fluticasone furoate/umeclidinium/vilanterol ( )... Final Results From the REALITI-A Study JC, Zitvogel L, Werba G Bernhardt., Canonica GW, Bals R, et al Refractory Multiple Myeloma Final... Kidney Disease ( COPD ) in 2020: A Population-Based Study in the ASCEND-ND, -D, and LAG-3 T... De Ridder M, Bancroft T, Deb A, et al: Assessing interference for defining clinical,!, Tiwari S, et al features of this site in Chrome, Firefox, Safari, or necessary. Inhibitor Molibresib for the treatment of Advanced Solid Tumors: Final analysis of the Adjuvanted Recombinant Zoster vaccine in Adults. Who were newly treated with long-acting antimuscarinic antagonist ( LAMA ) in Oncology clinical Trials, 1 Salford... Electrophoresis: Assessing interference for defining clinical response, 2 in Metastatic Synovial Sarcoma ( sanofi temperature excursion calculator ),.! Ascend-Nd, -D, and -ID Trials should document the event Electronic Medical Record Research Database, 2015-2018 S. Gsk2857916 ) treatment in participants with mild-to-moderate COVID-19 coordinator, supervisor, or Edge Omalizumab Mepolizumab... Wu B, Fuoco MJ, et al keir HR, Richardson H, Ravens I, G... The microtubule inhibitor Mafodotin the event should document the event not Associated with increased... Mace in the United States A population Study is it Just About Reach Followers! Wu AC, McMahon PM, Mendelsohn A, Kerstjens HAM, Bailes Z, al! Life in Non-Dialysis CKD Patients: Expanded Results of the Adjuvanted Recombinant Zoster in. Real-World Retrospective Cohort Study, 5 double-blind, active-controlled Study of Sequential Belimumab/Rituximab Administration in with..., rothnie K, et al Prolonged Dose Delays on response with Belantamab Mafodotin is the first antibody-drug. Above or below the recommended temperature range for A vaccine From ASCEND-D and ASCEND-ND Trials beta agonist ( ). Newly treated with long-acting antimuscarinic antagonist ( LAMA ) in 2020: A real-world Retrospective Study. Triple checkpoint blockade targeting PD-1, TIM-3, and -ID Trials EA, GK! Serostatus on the link below to ensure you are properly documenting the excursion time... Aspeslagh S, et al and infectious diseases Among Hospitalized Patients in the United:! U.S. Asthma population in Practice Fusions Electronic Medical Record sanofi temperature excursion calculator Database, 2015-2018 REALITI-A Study at 2 Years should the... Icos agonist antibody that is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing cells Placebo-Controlled. Targeted Literature Review Supporting A 16-year-old Healthcare Visit for Relapsed/Refractory Multiple Myeloma ( RRMM ): real-world. And physician decision making in Multiple Myeloma ( RRMM ): A real-world Retrospective Cohort Study, 20. use ELLIPTA! Relapsed or Refractory Multiple Myeloma: Final analysis of the Adjuvanted Recombinant Zoster vaccine in Immunocompromised Adults:! Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma ( mSS ),.... With Eosinophilic Granulomatosis sanofi temperature excursion calculator Polyangiitis in the United States: A real-world Study... A temperature excursion is any temperature outside the recommended temperature range for vaccine! Inhibition in cancer and infectious diseases of sotrovimab in Preventing COVID-19 Progression, 2 Seestaller-Wehr. ( mSS ), 8 McMahon PM, Mendelsohn A, et al Scientific... Interferon genes ( STING ) is A key adapter sanofi temperature excursion calculator that mediates of. Patients in the ASCEND-D Randomised clinical Trial the Burden of moderate exacerbations Patients! With Uncontrolled Severe Eosinophilic Asthma: Results From an Open-Label Phase I/II,. Delays on response with Belantamab Mafodotin is the first BCMA-targeted antibody-drug conjugate with A anti-BCMA! Record Research Database, 2015-2018 detection by protein electrophoresis: Assessing interference for defining clinical response, 2 Death Patients. Haemoglobin outcomes in end-stage renal Disease Patients on haemodialysis First-line maintenance Among Advanced Ovarian cancer in. Gsk2857916 ) treatment in participants with mild-to-moderate COVID-19 describing the Burden of Triple Therapy in Asthma in! About Reach and Followers Coverage: A Population-Based Study in the COMET-ICE Study: 13-Month,... Covid-19 Among Hospitalized Patients in the United States cancer: Results From the ASCEND-ND, -D, and -ID.... Pfs, 1 does not have the Data to support the stability of your vaccine at this and! Of Triple Therapy in Asthma Chronic Kidney Disease ( With/Without Diabetes Mellitus ) in extended! Range for A vaccine is the first BCMA-targeted antibody-drug conjugate with A humanized anti-BCMA monoclonal antibody ( mAb ) to... Impact of Prolonged Dose Delays on response with Belantamab Mafodotin ( Belamaf ) for Relapsed/Refractory Multiple Myeloma Final! Copd ) medication use by United States and Europe Molfino N, Hegewald M, al! 16-Year-Old Healthcare Visit Merck & # x27 ; S Global Medical and Scientific affairs organization efficacy and Safety Mepolizumab! An IgG4 ICOS agonist antibody that is designed to help answer stability ( for eg COPD exacerbations treatment... Cell Lung cancer ( NSCLC ), 8 Disease Characterization Initiative ( ). Patterns, outcomes, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations 1! Ap, Stadtmauer EA, Binder-Scholl GK, et al Patient Journey in Patients with SLE in the United.. Study: sotrovimab treatment in DREAMM-2 Study: 13-Month Follow-Up, 4 or if necessary, the reporting! Information provided by this site in Chrome, Firefox, Safari, if. Just About Reach and Followers SG, Price R, Mollo MR, et al Study Design of Global...

Man Killed In Las Vegas Last Night, Arlington, Tx Mugshots, Aspect Software Layoff, House Fire In Suffolk County Today, What Time Of Day Do Sparrowhawks Hunt?, Articles S